Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-22-308032
Filing Date
2022-12-19
Accepted
2022-12-19 10:17:04
Documents
14
Period of Report
2022-12-19
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d430132d8ka.htm   iXBRL 8-K/A 30513
2 EX-99.1 d430132dex991.htm EX-99.1 19326
6 GRAPHIC g430132g1219091123857.jpg GRAPHIC 6125
  Complete submission text file 0001193125-22-308032.txt   193057

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA wve-20221219.xsd EX-101.SCH 2875
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE wve-20221219_lab.xml EX-101.LAB 18634
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE wve-20221219_pre.xml EX-101.PRE 11689
8 EXTRACTED XBRL INSTANCE DOCUMENT d430132d8ka_htm.xml XML 4004
Mailing Address 733 CONCORD AVENUE CAMBRIDGE MA 02138
Business Address 7 STRAITS VIEW #12-00, MARINA ONE EAST TOWER SINGAPORE U0 018936 617-949-2900
Wave Life Sciences Ltd. (Filer) CIK: 0001631574 (see all company filings)

EIN.: 000000000 | State of Incorp.: U0 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-37627 | Film No.: 221469907
SIC: 2834 Pharmaceutical Preparations